💉 Sarepta Therapeutics’ Duchenne therapy gets accelerated approval; MPP grants sub-licenses for Nilotinib generics; Diabetes rates only going up

#369 | Filling AMR knowledge gaps; One compound v 12 viruses; Mosquitoes invade Europe

Hello, dear reader. Welcome back to The Kable for a quick look back at the week that was for the life sciences.

Yesterday, the US FDA granted accelerated approval to Sarepta Therapeutics’ Elevidys, which is the first gene therapy for Duchenne muscular dystrophy. The accelerated approval means that a late-stage trial is still ongoing, and if the final res…